Share Twitter LinkedIn Facebook Email Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses The Allure To The Immune Checkpoint Inhibitors. At Kidney Cancer Association National Patient September 22, 2018.
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO Kidney 4 Mins Read
Impact of Latino Ethnicity on Gut Microbiome in mRCC: ASCO 2024 Study – Regina Barragan-Carillo, Phd – City of Hope ASCO Annual Meeting 2 Mins Read
